Skip to main content
SpringerLink
Log in

Prognosis of Neuropsychiatric Systemic Lupus Erythematosus

  • Chapter
  • First Online:
Neuropsychiatric Systemic Lupus Erythematosus

  • 599 Accesses

Abstract

It is still a matter of debate whether mortality rate is higher in SLE patients with neuropsychiatric (NP) symptoms compared to those without them. Probably this situation is based on the difference in the character of each cohort and also on the vagueness of the definition/diagnosis of NPSLE, even after 1999. Although NPSLE has been repeatedly detected as one of the predictive factors for poor prognosis, NPSLE itself is not a common direct cause of death. It is more likely that patients with NPSLE tend to suffer from more recalcitrant lupus disease activities requiring intense immunosuppressive treatment or sometimes too severe to control. However, more and more advanced brain imaging , understanding on neuroscience and pathophysiology of NPSLE, and novel targeted-therapies are emerging. Thus we would expect better prognosis , cognitive/psychological functions and qualities of life for patients with NPSLE in near future.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599–608.

    Article  Google Scholar 

  2. Unterman A, et al. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum. 2011;41:1–11.

    Article  PubMed  Google Scholar 

  3. Sibley JT, et al. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. J Rheumatol. 1992;19:47–52.

    CAS  PubMed  Google Scholar 

  4. Karassa FB, et al. Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med. 2000;109:628–34.

    Article  CAS  PubMed  Google Scholar 

  5. Ginzler EM, et al. A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. Arthritis Rheum. 1982;25:601–11.

    Article  CAS  PubMed  Google Scholar 

  6. Jonsen A, et al. Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: increased morbidity but low mortality. Rheumatology. 2002;41:1308–12.

    Article  CAS  PubMed  Google Scholar 

  7. Hanly JG, et al. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2010;69:529–35.

    Article  CAS  PubMed  Google Scholar 

  8. Zirkzee EJ, et al. Mortality in neuropsychiatric systemic lupus erythematosus (NPSLE). Lupus. 2014;23:31–8.

    Article  CAS  PubMed  Google Scholar 

  9. Arinuma Y, et al. Brain MRI in patients with diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus. Lupus Sci Med. 2014;1:e000050.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Shimizu Y, et al. Post-steroid neuropsychiatric manifestations are significantly more frequent in SLE compared with other systemic autoimmune diseases and predict better prognosis compared with de novo neuropsychiatric SLE. Autoimmun Rev. 2016;15:786–94.

    Article  PubMed  Google Scholar 

  11. Kono M, et al. Long-term outcome in Japanese patients with lupus nephritis. Lupus. 2014;23:1124–32.

    Article  CAS  PubMed  Google Scholar 

  12. Mok CC, et al. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65:2154–60.

    Article  CAS  PubMed  Google Scholar 

  13. Yap DY, Tang CS, Ma MK, Lam MF, Chan TM. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant. 2012;27:3248–54.

    Article  PubMed  Google Scholar 

  14. Shinjo SK, et al. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum. 2010;62:855–62.

    Article  CAS  PubMed  Google Scholar 

  15. Monahan RC, et al. Neuropsychiatric symptoms in systemic lupus erythematosus: impact on quality of life. Lupus. 2017;26:1252–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Magro-Checa C, et al. Outcomes of neuropsychiatric events in systemic lupus erythematosus based on clinical phenotypes; prospective data from the Leiden NP SLE cohort. Lupus. 2017;26:543–51.

    Article  CAS  PubMed  Google Scholar 

  17. Gladman D, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363–9.

    Article  CAS  PubMed  Google Scholar 

  18. Magro-Checa C, et al. Changes in white matter microstructure suggest an inflammatory origin of neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 2016;68:1945–54.

    Article  CAS  Google Scholar 

  19. Zirkzee EJ, et al. Prospective study of clinical phenotypes in neuropsychiatric systemic lupus erythematosus; multidisciplinary approach to diagnosis and therapy. J Rheumatol. 2012;39:2118–26.

    Article  PubMed  Google Scholar 

  20. Fujieda Y, et al. Predominant prevalence of arterial thrombosis in Japanese patients with antiphospholipid syndrome. Lupus. 2012;21(14):1506.

    Article  CAS  PubMed  Google Scholar 

  21. Cervera R, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019–27.

    Article  PubMed  Google Scholar 

  22. Bernatsky S, et al. Mortality related to cerebrovascular disease in systemic lupus erythematosus. Lupus. 2006;15:835–9.

    Article  CAS  PubMed  Google Scholar 

  23. Otomo K, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012;64:504–12.

    Article  CAS  PubMed  Google Scholar 

  24. Sciascia S, et al. GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology. 2013;52:1397–403.

    Article  PubMed  Google Scholar 

  25. Oku K, et al. How to identify high-risk APS patients: clinical utility and predictive values of validated scores. Curr Rheumatol Rep. 2017;19:51.

    Article  PubMed  Google Scholar 

  26. Hanly JG. Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol. 2014;10:338–47.

    Article  CAS  PubMed  Google Scholar 

  27. Hanly JG, et al. Screening for cognitive impairment in systemic lupus erythematosus. J Rheumatol. 2012;39(7):1371.

    Article  PubMed  Google Scholar 

  28. Denburg SD, Denburg JA. Cognitive dysfunction and antiphospholipid antibodies in systemic lupus erythematosus. Lupus. 2003;12:883–90.

    Article  CAS  PubMed  Google Scholar 

  29. Hanly JG, et al. Cognitive function in systemic lupus erythematosus: results of a 5-year prospective study. Arthritis Rheum. 1997;40:1542–3.

    Article  CAS  PubMed  Google Scholar 

  30. Waterloo K, et al. Neuropsychological function in systemic lupus erythematosus: a five-year longitudinal study. Rheumatology. 2002;41:411–5.

    Article  CAS  PubMed  Google Scholar 

  31. Ainiala H, et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum. 2001;45:419–23.

    Article  CAS  PubMed  Google Scholar 

  32. Hanly JG, et al. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Rheumatol. 2004;31:2156–62.

    PubMed  Google Scholar 

  33. Sanna G, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol. 2003;30:985–92.

    PubMed  Google Scholar 

  34. Hirohata S, et al. Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study. Clin Rheumatol. 2009;28:1319–23.

    Article  PubMed  Google Scholar 

  35. Abe G, et al. Brain MRI in patients with acute confusional state of diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus. Mod Rheumatol. 2017;27:278–83.

    Article  CAS  PubMed  Google Scholar 

  36. Barile-Fabris L, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis. 2005;64:620–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Neuwelt CM, et al. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med. 1995;98:32–41.

    Article  CAS  PubMed  Google Scholar 

  38. Stojanovich L, et al. Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study). Lupus. 2003;12:3–7.

    Article  CAS  PubMed  Google Scholar 

  39. Neuwelt CM. The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus. Ther Apher Dial. 2003;7:173–82.

    Article  PubMed  Google Scholar 

  40. Camara I, et al. Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a series of 52 patients from a single centre. Clin Exp Rheumatol. 2014;32:41–7.

    PubMed  Google Scholar 

  41. Cobo-Ibanez T, et al. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin Arthritis Rheum. 2014;44:175–85.

    Article  CAS  PubMed  Google Scholar 

  42. Tokunaga M, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66:470–5.

    Article  CAS  PubMed  Google Scholar 

  43. Ginzler E, et al. Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. Arthritis Rheum. 1975;18:27–34.

    Article  CAS  PubMed  Google Scholar 

  44. Bertsias GK, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69:2074–82.

    Article  CAS  PubMed  Google Scholar 

  45. Khamashta MA, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995;332:993–7.

    Article  CAS  PubMed  Google Scholar 

  46. Crowther MA, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349:1133–8.

    Article  CAS  PubMed  Google Scholar 

  47. Finazzi G, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005;3:848–53.

    Article  CAS  PubMed  Google Scholar 

  48. Cohen H, et al. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol. 2016;3:e426–36.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Chau SY, Mok CC. Factors predictive of corticosteroid psychosis in patients with systemic lupus erythematosus. Neurology. 2003;61:104–7.

    Article  PubMed  Google Scholar 

  50. Bethea HN, et al. Redirecting the substrate specificity of heparan sulfate 2-O-sulfotransferase by structurally guided mutagenesis. Proc Natl Acad Sci U S A. 2008;105:18724–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

I appreciate supports and advice from Drs. Yuichiro Fujieda, Kenji Oku, Yuka Shimizu, Naoki Ohnishi, and Tatsuya Atsumi.

Author information

Authors and Affiliations

  1. Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

    Shinsuke Yasuda

Authors
  1. Shinsuke Yasuda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shinsuke Yasuda .

Editor information

Editors and Affiliations

  1. Department of Rheumatology, Nobubara Hospital, Tatsuno, Hyogo, Japan

    Shunsei Hirohata

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Yasuda, S. (2018). Prognosis of Neuropsychiatric Systemic Lupus Erythematosus. In: Hirohata, S. (eds) Neuropsychiatric Systemic Lupus Erythematosus. Springer, Cham. https://doi.org/10.1007/978-3-319-76496-2_12

Download citation

Publish with us

Policies and ethics

Search

Navigation